Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,986 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small-Cell Lung Cancer (SCLC) Clear all
Completed Phase 2 Interventional Results available

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

NCT00514215
View directory record Official record
Conditions
Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery
Biological · Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 9, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

NCT02949843
View directory record Official record
Conditions
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Targeted Molecular Therapy, Tyrosine Kinase Inhibitor
Drug · Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 9, 2026, 5:09 PM EDT
Not yet recruiting Early Phase 1 Interventional

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

NCT06979661
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Interventions
Haystack™ ctDNA Assay
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 1 Interventional

RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER

NCT02029729
View directory record Official record
Conditions
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
Interventions
omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 9, 2026, 5:09 PM EDT
Not yet recruiting Not applicable Interventional

Biomarker Testing to Predict Radiation-Related Heart Disease in Lung Cancer Patients

NCT07869329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Radiation-Induced Cardiac Disease
Interventions
Serum Pro-N-Cadherin Biomarker Assessment, Echocardiogram
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Recruiting Phase 1 Interventional

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

NCT07617337
View directory record Official record
Conditions
ALK Positive Non-small Cell Lung Cancer
Interventions
AQUA07, Lorlatinib
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Withdrawn Phase 3 Interventional

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
BMS-986205, Nivolumab, Chemotherapy
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 9, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

NCT01948141
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
nintedanib
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 9, 2026, 5:09 PM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00112060
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
PT-523 for Injection
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

NCT04484142
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
DS-1062a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

NCT00449020
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 9, 2026, 5:09 PM EDT
Completed No phase listed Observational

Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs

NCT01346280
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (Stage III), Colon Cancer (Stage II &Amp; III), Rectal Cancer (Stage III)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,079 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 9, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

NCT00907179
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LBH 589, Pemetrexed
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 9, 2026, 5:09 PM EDT
Not listed Phase 3 Interventional

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

NCT00246727
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Selected Vegetable and Herb Mix
Drug
Lead sponsor
Sun Farm Corporation
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Oct 9, 2026, 5:09 PM EDT
Not listed No phase listed Observational

Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting

NCT05826756
View directory record Official record
Conditions
Lung Cancer Patients, Caregivers
Interventions
There are no interventions in this study. All participants complete online surveys.
Other
Lead sponsor
LUNGevity Foundation
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

NCT00019331
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Melanoma (Skin), Pancreatic Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, ras peptide cancer vaccine, sargramostim, DetoxPC
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 9, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Cemiplimab-Rwlc
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Recruiting Phase 2 Interventional

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446
View directory record Official record
Conditions
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
23
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Recruiting Phase 1 Interventional

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

NCT07545954
View directory record Official record
Conditions
Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions
DSP-0390, Atezolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 9, 2026, 5:09 PM EDT
Terminated Phase 1 Interventional

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

NCT02649673
View directory record Official record
Conditions
Small Cell Lung Cancer, Ovarian Cancer
Interventions
LCL161, Topotecan, Pegylated GCSF (PEG-GCSF)
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 9, 2026, 5:09 PM EDT
Terminated Phase 2 Interventional Results available

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

NCT02403895
View directory record Official record
Conditions
Squamous Non Small Cell Lung Cancer
Interventions
Open-label AZD2014, paclitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 9, 2026, 5:09 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

NCT00367601
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Bevacizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Galesburg, Illinois • Bloomington, Indiana • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 9, 2026, 5:09 PM EDT